Aprepitant

🧮 Dose calculator

Chemotherapy-induced nausea and vomiting · Regimen source: FDA Emend · 2.1

• • With a corticosteroid and a 5-HT3 antagonist. 6 months to <12 y or unable to swallow: suspension per Table 3. FDA Emend · 2.1

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Emend · 8.1

  “Risk Summary There are insufficient data on use of EMEND in pregnant women to inform a drug associated risk.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Emend · 8.2

  “Risk Summary Lactation studies have not been conducted to assess the presence of aprepitant in human milk, the effects on the breastfed infant, or the effects on milk production.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Emend · 8.4

  “The safety and effectiveness of EMEND for oral suspension have been established in pediatric patients 6 months of age and older and EMEND capsules in pediatric patients 12 years of age and older for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of HEC, including …”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Emend · 8.5

  “In general, use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal or cardiac function and concomitant disease or other drug therapy [see Clinical Pharmacology (12.3) ] .”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Emend · 8.3

  “Contraception Upon administration of EMEND, the efficacy of hormonal contraceptives may be reduced.”